Jenna D. Goldberg

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Hematology, Immunology +17

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · The Lancet · 2021 · 312 citations

Medicine, Hematology, Immunology +12

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation

Doris M. Ponce, Patrick Hilden, Christen L. Mumaw et al. · Blood · 2014 · 122 citations · Full text

Medicine, Surgery, Transplant Immunology +15

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Carolina Schinke, Cyrille Touzeau, Monique C. Minnema et al. · Journal of Clinical Oncology · 2023 · 89 citations

Medicine, Pharmacology, Pharmacotherapy +16

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

Ajai Chari, Cyrille Touzeau, Carolina Schinke et al. · The Lancet Haematology · 2025 · 83 citations · Full text

Medicine, Oncology, Pharmacology +12